Nu Skin Enterprises Inc (NUS) Fair Value & Analysis

Consumer Defensive · US · Market cap $244M · ISIN US67018T1051

What is Nu Skin Enterprises Inc really worth?

Nu Skin Enterprises Inc NUS · US

Price$4.84

Fair Value$23.42

Upside+383.9%

Quality65/100

A solid business, trading 79% below our fair value of $23.42.

As of Sep 3, 2026, the fair value of Nu Skin Enterprises Inc is $23.42 per share against a price of $4.84, so the fair value sits 384% above the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Nu Skin Enterprises Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Low debt · generates free cash flow

✓Ranks above peers (9/14)

Risks

!Weak Growth (revenue 5y −10.5 %/yr)

!Thin margins · 3.8% net margin

!Narrow moat 43/100

!The models disagree: range $16.94 to $59.13

!Weak on past: 28 out of 100

For context

·4.96% dividend yield

Evidence: High Range $16.94 – $59.13

Fair value as of: Sep 3, 2026

From 24 valuation models · updated 3 days ago

Share price −7.3% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

The price is below even our cautious bear case ($16.94). The market is more pessimistic than our downside scenario.
The model range is unusually wide ($16.94 to $59.13). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 3, 2026.

How to read this chart

60‑month range $4.57 – $52.25 · fair‑value band $16.94 – $59.13 · the $4.84 price screens below the $23.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 3, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Nu Skin Enterprises Inc (NUS) currently trades at $4.84, while our model-based Fair Value estimate is $23.42, implying the stock looks roughly 79.3% undervalued today. The Quality Score stands at 65/100 (solid quality), in the Consumer Defensive sector. Bull case: the Growth Earnings group reads highest at a median of $52.43 per share, and 22 of the 24 models we run sit above the $4.84 price. Bear case: the Growth DCF group reads lowest at $9.40, and 2 of the 24 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Nu Skin Enterprises Inc generated revenue of $1.4B at a net margin of 3.8%. Revenue declined 12.0% year over year. It earns a return on equity of 7.0%. Net debt stands at $126M. Fundamentals as of Sep 3, 2026

Our scenario range runs from $16.94 (bear case) to $59.13 (bull case); at $4.84, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at −36% fair-value upside, at 384%, NUS screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.5730 per share, which is 3.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence

Highest evidence

FCF DCF best evidence $7.75 $9.33 $12.19 82

Growth DCF $7.89 $9.40 $11.88 80

Owner Earnings $27.98 $34.11 $45.18 78

All 24 models by family

DCF Models

FCF DCF best evidence $7.75 $9.33 $12.19 82

Owner Earnings $27.98 $34.11 $45.18 78

5Y Revenue Exit $12.38 $18.37 $27.38 72

5Y EBITDA Exit $17.20 $26.53 $39.27 75

5Y P/E Exit $27.86 $44.59 $65.07 70

10Y Revenue Exit $9.79 $14.08 $18.99 67

10Y EBITDA Exit $12.66 $18.66 $25.50 69

10Y P/E Exit $18.25 $28.78 $39.62 64

Earnings-Based

Graham-Dodd $22.44 $36.01 $43.40 67

EPV $8.78 $9.75 $10.54 74

Dividend Discount

Gordon GGM $1.70 $1.95 $2.20 69

DDM Multi-Stage $1.70 $2.07 $2.47 67

Multiples

P/E Multiple $51.97 $69.29 $86.62 63

P/S Multiple $36.71 $48.94 $61.18 58

P/B Multiple $42.07 $56.10 $70.12 55

EV/EBIT $24.57 $32.53 $40.49 66

EV/EBITDA $29.45 $39.04 $48.62 67

EV/Revenue $17.74 $25.04 $32.34 54

Asset-Based

NCAV (Graham) $8.29 $11.11 $16.59 54

Growth DCF

Growth DCF $7.89 $9.40 $11.88 80

Rev-Margin DCF $12.38 $18.56 $26.28 73

Economic Profit

Residual Income $17.03 $23.55 $77.07 64

ROIC Compounder $8.78 $9.75 $10.54 72

Growth Earnings

Growth-Adj P/E $36.70 $52.43 $68.15 67

Widest divergence: Growth Earnings ($52.43) versus Dividend Discount ($1.95). Highest evidence: FCF DCF (82).

Notify me when NUS reaches fair value

Put NUS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 4.5

P/S ratio 0.48 P/E × margin

EPS (TTM) $1.08 price ÷ EPS = P/E 4.5

Dividend yield 5.0% payout 22.2%

Net margin 10.8% FY2025

Return on equity 7.0% TTM

More key figures

Profitability

Return on assets (EBIT) 3.4% avg 5y

Operating margin 1.8% TTM

Growth

Revenue (TTM) $1.4B TTM

Revenue growth (YoY) −12.0% 3y avg −12.6%

EPS growth (YoY) −98.2%

Balance sheet & cash flow

Free cash flow $46.0M FY2025

Net debt $126M FY2025 · ≈ 2.7 yrs of FCF

Figures from reported company fundamentals · as of Sep 3, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 65/100

Of which business quality 63 · Market factors (momentum, volatility) 19

Profitability 74

Margins and returns on capital today

Quality Growth 52

Are margins and returns improving?

Cashflow 24

Earnings quality: real cash, not paper profit

Fin. Strength 71

Balance sheet, leverage, solvency risk

Investment 99

Disciplined investing over empire-building

Low Volatility 46

Calm price path (market factor)

Momentum 13

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 76

Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide.

Full company description

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands. The company also provides wellness products, such as ageLOC TRME, LifePak, and Beauty Focus. In addition, it is the research and product development of skin care products, nutritional supplements, and devices. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center and independent marketers. It serves Mainland China; South Korea; Southeast Asia/Pacific, which includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; Americas, comprising Canada, Latin America and the United States; Japan; Hong Kong/Taiwan, consists of Macau; and Europe & Africa, which includes markets in Europe as well as South Africa. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Nu Skin Enterprises Inc reported revenue of $1.5B in FY2025 versus $2.7B in FY2021, a compound −13.8%/yr. Reported net income was $160M in FY2025, compounding +2.1%/yr from FY2021.

Growth Quality 26/100

Revenue growth is weak, negative or inconsistent.

Latest Revenue (FY 2025)

$1.5B

Latest YoY

−14.3%

Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

−12.6%

Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

−10.5%

Avg. revenue growth/yr (30Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+4.9%

Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years, EBIT basis) plus dividend yield: value created per share and year.

≈ −12.7% (approximate, leans on 2025) · in USD

Earnings growth per share plus dividend yield: the value created per share and year.

Earnings growth per share−17.7%

Dividend yield5.0%

Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 0.5% vs 10Y 2.2%, steady

Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10.0% (2020) → 6.1% (2025) · falling

Worst earnings drop242% (2024) (loss year, drop beyond 100%) · in USD

⚠ Revenue per share shrinking 1.9%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

⚠ Final year 2025 sits 184% above its own trend (e.g. a one-off disposal gain), so this rate uses the operating basis instead of reported profit

Revenue −13.8%/yr

FY21 $2.7B

FY22 $2.2B

FY23 $2.0B

FY24 $1.7B

FY25 $1.5B

Net income +2.1%/yr

FY21 $147M

FY22 $105M

FY23 $8.6M

FY24 −$147M

FY25 $160M

Character of growth · EPS growth decomposed (2014-2025) −4.9 % p.a.

Revenue per share −1.6 %

of which total revenue −3.3 % · buybacks/dilution +1.8 %

EBIT margin −11.2 %

Tax rate +1.8 %

Residual (interest, one-offs) +7.0 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

Watch NUS: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nu Skin Enterprises Inc · Fair Value
$23.42 +79%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/NUS.US" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Nu Skin Enterprises Inc · Fair Value</span><br><b style="font-size:20px">$23.42</b> <span style="color:#7BB290;font-weight:700;font-size:14px">+79%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Nu Skin Enterprises Inc Fair Value". https://www.fairvalue-calculator.com/stock/NUS.US

Peer Group

Household & Personal Products · 245 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 65 · Above median

Return on equity (TTM) 7% · Above median

Return on assets 4% · Above median

Net margin (TTM) 4% · Below median

Operating margin (TTM) 2% · Below median

Revenue growth −12% · Bottom 25%

Dividend yield (TTM) 5.0% · Above median

Debt / equity 0.25× · Higher than median

Valuation Multiples vs Household & Personal Products median · lower = cheaper

P/E (TTM) 4.5× · Cheaper than 75% of peers

P/B 0.30× · Cheaper than 75% of peers

P/S (TTM) 0.17× · Cheaper than 75% of peers

P/FCF 5.3× · Pricier than median

EV/EBITDA 1.6× · Cheaper than 75% of peers

PEG 0.78× · Cheaper than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

This stock

Sector peers

VALUE0 · sector 27

FUTURE0 · sector 9

PAST28 · sector 27

HEALTH87 · sector 98

DIVIDEND99 · sector 56

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Sep 3, 2026).

Stock	Price	Fair Value	vs Fair Value
L'Oréal S.A LORL	C$24.76	C$22.64	−9%
Unilever PLC UNA	€55.92	€40.47	−28%
Colgate-Palmolive Company CL	$90.75	$55.28	−39%
500696 500696	₹2,093	₹641.55	−69%
Hindustan Unilever Limited HINDUNILVR	₹2,015	₹789.46	−61%
Kenvue Inc KVUE	$18.95	$10.97	−42%
Kimberly-Clark Corporation KMB	$109.55	$79.71	−27%
Henkel AG HEN3	€76.42	€85.95	+12%
The Estée Lauder Companies Inc ESLA	€86.54	€18.84	−78%
Church & Dwight Co CHD	$101.26	$65.12	−36%

Compare Nu Skin Enterprises Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Nu Skin Enterprises Inc (NUS) overvalued or undervalued?

As of Sep 3, 2026, our model estimates a fair value of $23.42 versus a price of $4.84, about +384% upside (undervalued).

What is the fair value of NUS?

Our model-based fair value for Nu Skin Enterprises Inc is $23.42 (as of Sep 3, 2026), built from audited fundamentals. The current price: $4.84.

What is the quality score of NUS?

Nu Skin Enterprises Inc has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Nu Skin Enterprises Inc (NUS)?

Our model-based price target is the fair value of $23.42 (as of Sep 3, 2026) from 24 valuation models. Cautious scenario $16.94, optimistic scenario $59.13. It is a calculation from audited fundamentals, not an analyst target.

What is the Nu Skin Enterprises Inc stock forecast for 2026?

Our models put fair value at $23.42, about +384% upside versus a price of $4.84 (undervalued). Cautious scenario $16.94, optimistic scenario $59.13. The calculation is refreshed regularly with new filings.

What is the revenue of Nu Skin Enterprises Inc (NUS)?

Nu Skin Enterprises Inc reported trailing-twelve-month revenue of about $1.4B (latest available figure, as of Sep 3, 2026).

What is the net profit margin of NUS?

The net profit margin of Nu Skin Enterprises Inc is about 3.8%, meaning it keeps roughly 3.8% of revenue as net income. Based on the latest reported figures.

Does Nu Skin Enterprises Inc pay a dividend?

Nu Skin Enterprises Inc currently shows a dividend yield of about 4.96% relative to its recent price (as of Sep 3, 2026).

Free · no account needed

Watch Nu Skin Enterprises Inc in the live analysis

One click puts Nu Skin Enterprises Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.